Page last updated: 2024-10-30

loperamide and Leiomyosarcoma

loperamide has been researched along with Leiomyosarcoma in 1 studies

Loperamide: One of the long-acting synthetic ANTIDIARRHEALS; it is not significantly absorbed from the gut, and has no effect on the adrenergic system or central nervous system, but may antagonize histamine and interfere with acetylcholine release locally.
loperamide : A synthetic piperidine derivative, effective against diarrhoea resulting from gastroenteritis or inflammatory bowel disease.

Leiomyosarcoma: A sarcoma containing large spindle cells of smooth muscle. Although it rarely occurs in soft tissue, it is common in the viscera. It is the most common soft tissue sarcoma of the gastrointestinal tract and uterus. The median age of patients is 60 years. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p1865)

Research Excerpts

ExcerptRelevanceReference
"Perifosine (NSC 639966) is a synthetic, substituted heterocyclic alkylphosphocholine that acts primarily at the cell membrane targeting signal transduction pathways."2.71A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. ( Alberti, D; Arzoomanian, R; Binger, K; Kolesar, J; Marnocha, R; Tutsch, K; Van Ummersen, L; Volkman, J; Wilding, G, 2004)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Van Ummersen, L1
Binger, K1
Volkman, J1
Marnocha, R1
Tutsch, K1
Kolesar, J1
Arzoomanian, R1
Alberti, D1
Wilding, G1

Trials

1 trial available for loperamide and Leiomyosarcoma

ArticleYear
A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Nov-15, Volume: 10, Issue:22

    Topics: Adult; Aged; Antineoplastic Agents; Dexamethasone; Dose-Response Relationship, Drug; Drug Administra

2004